Key Insights on Gross Profit: Takeda Pharmaceutical Company Limited vs HUTCHMED (China) Limited

Takeda vs. HUTCHMED: A Decade of Growth in Pharmaceuticals

__timestampHUTCHMED (China) LimitedTakeda Pharmaceutical Company Limited
Wednesday, January 1, 2014197640001256834000000
Thursday, January 1, 2015674260001271973000000
Friday, January 1, 2016597520001173296000000
Sunday, January 1, 2017653830001274610000000
Monday, January 1, 2018701650001437534000000
Tuesday, January 1, 2019447380002201424000000
Wednesday, January 1, 2020394570002203504000000
Friday, January 1, 2021978940002462160000000
Saturday, January 1, 20221153060002783406000000
Sunday, January 1, 20234535520002832257000000
Monday, January 1, 20242832257000000
Loading chart...

Unleashing the power of data

A Tale of Two Giants: Takeda vs. HUTCHMED

In the ever-evolving pharmaceutical landscape, Takeda Pharmaceutical Company Limited and HUTCHMED (China) Limited stand as prominent players. Over the past decade, Takeda has consistently demonstrated its dominance, with gross profits soaring to approximately 2.8 trillion yen by 2023, marking a 125% increase since 2014. In contrast, HUTCHMED, while smaller in scale, has shown remarkable growth, with gross profits increasing by over 2,000% from 2014 to 2023.

Key Insights

  • Takeda's Steady Climb: From 2014 to 2023, Takeda's gross profit grew steadily, reflecting its robust market strategies and global reach.
  • HUTCHMED's Rapid Growth: Despite its smaller size, HUTCHMED's gross profit surged, particularly in 2023, indicating its potential in the competitive market.

The data highlights the contrasting growth trajectories of these two companies, offering valuable insights into their strategic directions and market positions.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025